BDBM513847 5-(2-cyano-5-(((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)amino)imidazo[1,2-c]pyrimidin-8-yl)-N,1-dimethyl-1H-pyrazole-3-carboxamide::US11091495, Example 208::US11091495, Example 211::US11220509, Example 208::US11485738, Example 208
SMILES CNC(=O)c1cc(-c2cnc(NCc3c4CCOc4ccc3F)n3cc(nc23)C#N)n(C)n1
InChI Key InChIKey=PUUDAUWNSZGWMD-UHFFFAOYSA-N
Data 7 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 7 hits for monomerid = 513847
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:An aliquot of each serial dilution of test compound was added to deep 384 well plate using Acoustic Technology instrument (Echo 550, LabCyte) contain...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 100nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
TargetHistone-binding protein RBBP4/Histone-lysine N-methyltransferase EZH2/Polycomb protein EED/Polycomb protein SUZ12/Zinc finger protein AEBP2(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 300nMAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
